{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:02:08Z","timestamp":1771851728520,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Membranous glomerulonephritis (MGN) is a rare extra-hematological autoimmune complication of chronic lymphocytic leukemia (CLL), clinically characterized by nephrotic-range proteinuria and, less frequently, renal failure. Because of the rarity of this condition, there is no standardized treatment. Chlorambucil and fludarabine-based regimens, possibly combined with rituximab, have been historically the most frequent therapeutic approaches, with renal response obtained in about two-third of the patients. However, responses are often transient and partial. Here we describe the first patient with rituximab-refractory, CLL-related MGN successfully treated with the Bcl-2 antagonist venetoclax. Nephrotic syndrome resolved as soon as three months after venetoclax initiation, with no unexpected toxicities. At the last follow-up, 17 months after venetoclax start, renal response persists, with proteinuria below 0.5 g\/24 hours. This case suggests that targeted agents, particularly Bcl-2 antagonists, might be suitable options for patients with renal autoimmune disorders arising in the context of CLL.<\/jats:p>","DOI":"10.3389\/fonc.2023.1108994","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:31:25Z","timestamp":1682051485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ester","family":"Lovato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isacco","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020282","article-title":"Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs","volume":"12","author":"Vitale","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66583-X","article-title":"Glomerulonephritis","volume":"365","author":"Chadban","year":"2005","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal b-cell lymphocytosis: the Mayo clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.10.009","article-title":"Membranous nephropathy: Core curriculum 2021","volume":"77","author":"Alsharhan","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.39744","article-title":"Bcl-2 as a therapeutic target in human tubulointerstitial inflammation","volume":"68","author":"Ko","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/bmj.4.5937.164","article-title":"Letter: Nephrotic syndrome in chronic lymphatic leukaemia","volume":"4","author":"Cameron","year":"1974","journal-title":"Br Med J"},{"key":"B10","article-title":"Membranous nephropathy long-term follow-up and association with neoplasia","volume":"46","author":"Row","year":"1975","journal-title":"Ateneo Parmense Acta Biomed"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831215)52:12<2253::AID-CNCR2820521215>3.0.CO;2-L","article-title":"Membranous nephropathy associated with an unusual phenotype of chronic lymphocytic leukemia","volume":"52","author":"White","year":"1983","journal-title":"Cancer"},{"key":"B12","article-title":"Nephrotic syndrome associated with chronic lymphocytic leukemia: an immunological and pathological study","volume":"31","author":"Touchard","year":"1989","journal-title":"Clin Nephrol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.270","article-title":"Glomerulonephritis in chronic lymphocytic leukemia and related b-cell lymphomas","volume":"42","author":"Moulin","year":"1992","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000188915","article-title":"Effect of cyclosporin a in a patient with refractory nephrotic syndrome associated with b chronic lymphocytic leukemia","volume":"72","author":"Eisterer","year":"1996","journal-title":"Nephron"},{"key":"B15","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1016\/S0272-6386(99)70329-X","article-title":"Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine","volume":"33","author":"Butty","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"B16","article-title":"Fludarabine therapy in chronic lymphocytic leukemia-associated severe nephrotic syndrome","volume":"85","author":"Abdel-Raheem","year":"2000","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000013626","article-title":"Membranous glomerulonephritis with nephrotic syndrome associated with chronic lymphocytic leukemia","volume":"20","author":"Yahata","year":"2000","journal-title":"Am J Nephrol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.5790493.x","article-title":"Kidney involvement and renal manifestations in non-hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients","volume":"67","author":"Da'as","year":"2001","journal-title":"Eur J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20109","article-title":"Membranous glomerulonephritis in chronic lymphocytic leukemia","volume":"76","author":"Ziakas","year":"2004","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.humpath.2010.09.009","article-title":"Patterns of glomerular injury in kidneys infiltrated by lymphoplasmacytic neoplasms","volume":"42","author":"Kowalewska","year":"2011","journal-title":"Hum Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2012.743912","article-title":"Fludarabine in chronic lymphocytic leukemia with membranous nephropathy","volume":"35","author":"Rocca","year":"2013","journal-title":"Ren Fail"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.07.008","article-title":"Membranous glomerulopathy with light chain-restricted deposits: A clinicopathological analysis of 28 cases","volume":"2","author":"Best Rocha","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2018.05.006","article-title":"[Chronic lymphoid leukemia and renal complication: Report on 10 cases from marseille over 16 years]","volume":"39","author":"Vial","year":"2018","journal-title":"Rev Med Interne."},{"key":"B24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13000-021-01120-4","article-title":"The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia\/small lymphocytic lymphoma from a large single Chinese center","volume":"16","author":"Wang","year":"2021","journal-title":"Diagn Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.08.038","article-title":"The case | nephrotic syndrome in a patient with chronic lymphocytic leukemia","volume":"99","author":"Ahmed","year":"2021","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870815)60:4<827::AID-CNCR2820600419>3.0.CO;2-A","article-title":"An autopsy study of 1206 acute and chronic leukemias (1958 to 1982)","volume":"60","author":"Barcos","year":"1987","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.611317","article-title":"Secondary membranous nephropathy. a narrative review","volume":"7","author":"Moroni","year":"2020","journal-title":"Front Med (Lausanne)."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008201","article-title":"Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs","volume":"137","author":"Vitale","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1108994\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:31:29Z","timestamp":1682051489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1108994\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":28,"alternative-id":["10.3389\/fonc.2023.1108994"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1108994","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1108994"}}